1222102-29-5

Developed by Dong-A ST, evogliptin was approved in 2015 in the Republic of Korea for blood glucose control in patients with diabetes mellitus type 2 (type 2 DM). Evogliptin is an orally bioavailable dipeptidyl peptidase IV (DPP-4) inhibitor, which acts to prevent insulin secretion following meals. Dong-A ST arranged licensing agreements with Geropharm and Eurofarma Laboratórios for the sale of evogliptin in various countries in eastern Europe and Brazil, respectively, pending future approvals. While a manufacturing route has not been disclosed to date, the most scalable published route is described below.

依格列汀 是一种口服有效的 DPP4 抑制剂，在小鼠模型中具有显著而持久的降糖效果。Evogliptin 还可通过诱导自噬来抑制肝细胞的炎症和纤维化信号的产生。Evogliptin 可用于 2 型糖尿病、骨质疏松症，肾功能损害以及慢性肝脏炎症的研究。